Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | USP2 | O75604 | 4/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | GRK6 | P43250 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL28201213 | 1.00 | TDP1 (0.69) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL10477625 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL3969884 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL5175145 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL3969889 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL10477623 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL5175147 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL21931671 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL20716523 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL22171064 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463681-B2 | Combination therapy for skin disorders | M. ALPHABET 1, L.L.C. (US) | 2019-11-05 | — | — | US | claimed |
| WO-2023087001-A1 | DRUG-RELEASING POLYMER COMPOSITION AND DEVICE | NOVAFLUX INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149603-A1 | DRUG-RELEASING POLYMER COMPOSITION AND DEVICE | NOVAFLUX INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-105362211-A | Nano-metal oxide-minocycline nano sustained-release gel as well as preparation method and application thereof | MOU JIE | 2016-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463681-B2 | Combination therapy for skin disorders | NR5A1, CYP17A1, HSD17B2 | TDP1 1629/4885KDM4E 3283/4885USP2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.